Roche won FDA approval for a supplemental license application of its chronic lymphocytic leukemia drug Gazyva, strengthening its case over rival GlaxoSmithKline and adding some ammo to its hemo-oncology arsenal.
Building on recent momentum of its molecular diagostics, Roche has nabbed a CE mark for a new assay designed to spot a type of herpesvirus using the company's latest rapid blood and plasma testing product lines.
Roche is decking the halls with diagnostics acquisitions and Bina Technologies is the company's latest target.
Roche snatched up DNA sequencing outfit Bina Technologies for an undisclosed sum, continuing its M&A winning streak and expanding its diagnostics footprint.
ImmunoGen watched its shares fall by 50% when partner Roche revealed disappointing results for the pair's targeted cancer drug, casting doubts on the biotech's technology for creating armed antibodies.
Roche has been charting promising numbers for its standout breast cancer drugs Kadcyla and Perjeta. But now the next-gen duo has failed to beat Herceptin and chemo in a late-stage study, putting a damper on Roche's plan to expand the market for its new drugs and sending its shares into a downward spiral.
Yet another big Phase III test of an experimental Alzheimer's drug has flopped. And this time it's Roche's turn to admit defeat.
Roche is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $488.8 million and get its hands on some proprietary technology.
Roche got a green light from U.S. regulatory authorities to expand the use of two tests from its cobas assay line used to detect serious viral infections like HIV, hepatitis B and C and West Nile.
Roche has launched the Laboratory-in-a-tube technology it acquired when it bought iQuum in April for $275 million up front and up to $175 million in milestone payments. Roche is making the system available in the U.S. and Europe.